Because of this phenomenon, HBOC patients with germline BRCA1 and BRCA2 mutations have an increased risk for the development of a number of neoplasms, particularly those arising in the breast as well as ovary and fallopian tube (9) (hereby referred to as “tubo-ovarian cancer”). Here, BRCA2 is linked to neoplasm.